Several classes of medications can trigger aplastic anemia, a rare condition where the bone marrow stops producing enough blood cells. The drugs most strongly linked include certain antibiotics (chloramphenicol), anticonvulsants (felbamate), anti-inflammatory drugs (NSAIDs like butazone), antithyroid medications (methimazole), gold salts used for rheumatoid arthritis, and sulfonamide antibiotics. The condition affects roughly 2 to 2.5 people per million each year in Western countries, and drugs are one of the most identifiable triggers.
How Drugs Damage the Bone Marrow
Drug-induced aplastic anemia doesn’t typically happen because a medication is directly poisonous to bone marrow cells. Instead, the drug provokes an abnormal immune response. The body’s own immune cells, specifically a type of white blood cell designed to kill threats, begin attacking the stem cells in the bone marrow that are responsible for producing red blood cells, white blood cells, and platelets. These immune cells release signaling molecules that push the stem cells toward programmed cell death, effectively shutting down blood cell production at its source.
This is why the condition can be so severe. It’s not just one type of blood cell that drops. All three major types decline simultaneously, a situation called pancytopenia. That means you can become anemic (low red cells), vulnerable to infections (low white cells), and prone to bleeding (low platelets) all at once.
Drugs With the Strongest Links
The medications implicated in aplastic anemia span several categories:
- Chloramphenicol: The most historically notorious cause. This antibiotic has been associated with aplastic anemia for decades, though the absolute risk is low. Even with eye drop formulations, the incidence is roughly 0.36 cases per million weeks of treatment, compared to a background rate of 0.04 per million weeks in people not using the drug.
- Anticonvulsants: Felbamate, a seizure medication, carries a black box warning specifically for aplastic anemia and liver failure. The risk is high enough that patients starting felbamate need blood work every two weeks for the first three months, then every 6 to 12 months after that.
- NSAIDs: Anti-inflammatory painkillers, particularly older ones like phenylbutazone (butazone), have been linked to marrow failure. The risk varies significantly between specific drugs in this class.
- Antithyroid medications: Methimazole and related drugs used to treat overactive thyroid are well-documented triggers. In a review of cases over 30 years, the median time from starting the medication to developing aplastic anemia was about 51 days.
- Gold salts and penicillamine: Both used for rheumatoid arthritis, these medications carry a recognized risk of bone marrow suppression.
- Sulfonamide antibiotics: Including trimethoprim/sulfamethoxazole, a widely prescribed antibiotic combination.
- Antituberculous drugs: Medications used to treat tuberculosis have been linked to aplastic anemia in case reports.
Why It Happens to Some People and Not Others
One of the most unsettling aspects of drug-induced aplastic anemia is its unpredictability. Most people who take these medications never develop any bone marrow problems. The reaction is classified as idiosyncratic, meaning it depends on the individual person’s biology rather than on how much drug they take.
The current understanding is that specific genetic variations in immune system proteins play a major role. Certain people carry immune cell receptors that, when exposed to a particular drug or its breakdown products, mistakenly identify bone marrow stem cells as threats. This explains why the reaction can’t be predicted by dose alone and why it strikes seemingly at random. That said, researchers have found that calling these reactions entirely “dose-independent” isn’t accurate either. The total amount of drug and its byproducts circulating in the body still factors into the equation, which is why higher-dose medications tend to carry greater risk.
How Quickly Symptoms Appear
Drug-induced aplastic anemia doesn’t develop overnight, but it can progress faster than many people expect. Data from antithyroid drug cases shows the onset ranges from as little as 20 days to as long as 8 months after starting the medication. About 70% of cases appeared within the first 3 months, and 94% within 6 months. Some patients reported early warning signs like sore throat and fever within just days of starting treatment, though these initial symptoms can easily be mistaken for a common infection.
The first measurable changes typically show up on blood tests before a person feels seriously ill. A dropping platelet count and a declining reticulocyte count (a measure of new red blood cells being produced) are early laboratory signals. For the patient, the symptoms that follow reflect the specific blood cells being lost: fatigue and pallor from low red cells, easy bruising or unusual bleeding from low platelets, and frequent or stubborn infections from low white cells.
How Diagnosis Works
Aplastic anemia is diagnosed when a person has persistently low counts across all three blood cell types for more than six months, combined with specific findings on a bone marrow biopsy. At minimum, a person needs to show at least two of the following: a neutrophil count (a key infection-fighting white cell) below 1.5 billion per liter, platelets below 50 billion per liter, or hemoglobin below 10 g/dL.
Severe aplastic anemia is defined by bone marrow cellularity below 25%, meaning the marrow is less than a quarter as active as it should be, along with more dramatic drops in blood counts. Very severe cases are distinguished by neutrophil counts dropping below 0.2 billion per liter, a level that leaves the body with almost no defense against bacterial infections.
Recovery After Stopping the Drug
The encouraging news is that drug-induced aplastic anemia has a better chance of reversing than many other forms. In a retrospective study of 136 aplastic anemia patients, about 13% experienced spontaneous remission, and having a drug as the identified cause was one of the independent predictors of that recovery. Among those who did recover on their own, the process was usually fast: the median time to remission was just 14 days from diagnosis, and 83% recovered within 50 days. Recovery was complete in 78% of those cases, and relapse was rare.
That said, 13% is still a minority of patients. Many people with drug-induced aplastic anemia will need active treatment, which can range from immune-suppressing therapy to stem cell transplantation depending on severity, age, and whether a suitable donor is available. The critical first step is always identifying and stopping the offending medication as quickly as possible, which is why regular blood monitoring matters so much for high-risk drugs like felbamate.
Why Monitoring Matters for High-Risk Medications
For medications with known aplastic anemia risk, blood count monitoring is the primary safety net. Felbamate’s prescribing guidelines spell this out explicitly: blood work before starting, every two weeks for the first three months, and every 6 to 12 months after that. The first 6 to 12 months carry the highest risk for idiosyncratic reactions.
If you’re taking any medication on the higher-risk list, knowing the early warning signs gives you a meaningful advantage. Unexplained fatigue that worsens over days to weeks, bruises appearing without clear cause, bleeding gums, frequent infections, or a general sense of feeling unwell can all signal falling blood counts. These symptoms overlap with many less serious conditions, but in the context of a medication known to carry this risk, they warrant prompt blood work rather than a wait-and-see approach.